What question did this study set out to answer?

To compare the safety profiles of abrocitinib, baricitinib, tofacitinib, and upadacitinib in treating atopic dermatitis based on adverse events reported to FAERS.

May 22, 2026Dermatologic TherapyOpen Access

Comparative Safety Analysis of JAK Inhibitors in the Treatment of Atopic Dermatitis: Based on the FAERS Database

View Full Paper

Ask AI

Bookmark

Authors

ZSZijun Song JYJianqin Yu HYHongyu YangUniversity of Science and Technology of China

Discussion

Member takes

Implication

Comparative trial analyzes adverse events in JAK inhibitors, highlighting distinct safety profiles for atopic dermatitis treatment.

Key Points

To compare the safety profiles of abrocitinib, baricitinib, tofacitinib, and upadacitinib in treating atopic dermatitis based on adverse events reported to FAERS.
Data from the FAERS database covering 2004 to 2024 was collected and analyzed.
Disproportionality analyses were performed using ROR, PRR, BCPNN, and MGPS.
Temporal distribution patterns of adverse events were evaluated.
5231 JAK inhibitor-related AEs were analyzed from the FAERS database.
Abrocitinib showed top AE signals for condition aggravated (ROR = 3.65) and therapeutic product effect incomplete (ROR = 20.74).
Baricitinib was linked to herpes zoster (ROR = 11.07) and eczema herpeticum (ROR = 45.71); Tofacitinib had a significant off-label use signal (ROR = 22.94).

Cite This Study

Song et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff39dd674f7c03778c674 https://doi.org/10.1155/dth/2138090

View Full Paper

Ask AI

Bookmark

May 22, 2026Dermatologic TherapyOpen Access

Comparative Safety Analysis of JAK Inhibitors in the Treatment of Atopic Dermatitis: Based on the FAERS Database

View Full Paper

Ask AI

Bookmark

Authors

ZSZijun Song JYJianqin Yu HYHongyu YangUniversity of Science and Technology of China

Discussion

Member takes

Implication

Comparative trial analyzes adverse events in JAK inhibitors, highlighting distinct safety profiles for atopic dermatitis treatment.

Key Points

To compare the safety profiles of abrocitinib, baricitinib, tofacitinib, and upadacitinib in treating atopic dermatitis based on adverse events reported to FAERS.
Data from the FAERS database covering 2004 to 2024 was collected and analyzed.
Disproportionality analyses were performed using ROR, PRR, BCPNN, and MGPS.
Temporal distribution patterns of adverse events were evaluated.
5231 JAK inhibitor-related AEs were analyzed from the FAERS database.
Abrocitinib showed top AE signals for condition aggravated (ROR = 3.65) and therapeutic product effect incomplete (ROR = 20.74).
Baricitinib was linked to herpes zoster (ROR = 11.07) and eczema herpeticum (ROR = 45.71); Tofacitinib had a significant off-label use signal (ROR = 22.94).

Cite This Study

Song et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff39dd674f7c03778c674 https://doi.org/10.1155/dth/2138090

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark